Please login to the form below

enzalutamide

This page shows the latest enzalutamide news and features for those working in and with pharma, biotech and healthcare.

EMA starts review of Xtandi in non-metastatic prostate cancer

Reported in February, the study showed that adding Xtandi (enzalutamide) to treatment with anti-androgen hormone therapy reduced the risk of disease spreading or death by 71% compared with hormone therapy

Latest news

J&J’s Erleada first US drug for non-metastatic prostate cancer

It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and Astellas and their Xtandi (enzalutamide) product, which has also been
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

The filings are based on the just-released results of the PROSPER trial, which show that adding Xtandi (enzalutamide) to treatment with anti-androgen hormone therapy reduced the risk of disease
Astellas extends phase III programme for Rydapt rival gilteritinib

Gilteritinib is one of a clutch of new drugs Astellas is banking on to inject renewed growth into its revenues as prostate cancer blockbuster Xtandi (enzalutamide) starts to slow down, and
Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

The US's largest drugmaker booked $141m from Xtandi (enzalutamide) in the second quarter, up from $131m in the first quarter of the year and flat on the last quarter of
Pfizer hits accelerator on Xtandi trial in early prostate cancer

Originally due to report in mid-2019, the large-scale PROSPER trial of Xtandi (enzalutamide) in patients with non-metastatic, castration-resistant prostate cancer will now generate top-line results later

More from news
Approximately 13 fully matching, plus 43 partially matching documents found.

Latest Intelligence

Cost containment and the German market

The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.
Deal Watch May 2016

The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Astellas: Ten years young

Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Dendreon appoints new R&D lead

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Medical Writers Required - Hertfordshire: Competitive

Market Access Consultant - Greater Manchester: Negotiable

Account Director, Healthcare Advertising Agency: Salary TBC

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Graduate Scientific Editor: DOE

Associate Scientific Director: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Manager: Negotiable

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Healthcare PR Senior Account Manager: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Medical Writer: Salary is DOE

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Director or Senior Account Director: Salary TBC

Sudler London - Account Director: Competitive

Subscribe to our email news alerts

PMHub

Add my company

Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....